140610.Kn
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
Business. The company operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
The company's capital structure is characterized by a debt-to-equity ratio of 0.61, indicating a moderate reliance on debt financing. However, its liquidity position is constrained, with a current ratio of 1.7 and negative free cash flow of -4915069990 KRW. The company's cash and equivalents of 1065175170 KRW are insufficient to cover its long-term debt of 8311059050 KRW, resulting in a net cash position that is negative after subtracting total debt.
Profitability metrics are severely negative, with a return on equity of -0.3932 and a return on assets of -0.1685. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating loss of -7189008370 KRW and net loss of -5335727080 KRW further underscore the company's financial distress.
The company's revenue of 25056000.0 KRW is not segmented by geographic region or product line in the available data, making it difficult to assess revenue concentration or diversification. However, the lack of segment-specific data suggests that the company may be heavily reliant on a single product or market, which could pose a concentration risk.
The company's growth trajectory is negative, with a significant operating and net loss in the most recent period. There is no indication of a recovery in the near term, as the company continues to report negative cash flows from operations and free cash flow. The absence of positive revenue growth or margin improvement signals a challenging outlook for the company.
The company faces significant financial risks, including liquidity constraints and a high probability of continued losses. The risk assessment indicates a medium liquidity risk, with the company's cash and equivalents insufficient to cover its long-term obligations. The dilution risk is currently low, but the company's financial position may necessitate additional financing, which could lead to share dilution in the future.
Recent financial filings and transcripts do not provide specific details on the company's strategic initiatives or operational changes. However, the continued negative operating performance and liquidity constraints suggest that the company may be exploring cost-cutting measures or restructuring efforts to stabilize its financial position.
- The company is experiencing significant financial distress, with large operating and net losses.
- Liquidity is constrained, with insufficient cash to cover long-term debt obligations.
- Profitability metrics are severely negative, indicating poor returns on equity and assets.
- The company's financial position may require additional financing, which could lead to share dilution.
- There is no indication of a recovery in the near term, with continued negative cash flows.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 140610.KN Market data — financials · 2026-05-26